Phase I trial of adjuvant chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil (CEF) for stage II breast cancer

Stephen E. Jones, Robert G. Mennel, George N. Peters, Mary Alice Westrick, Barry D. Brooks, Sally Moot Knox, Patty McGuffey

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Epirubicin is a new anthracycline with a potentially more favorable toxicity profile than the parent compound, doxorubicin. Accordingly, the feasibility and toxicity of 6 courses of adjuvant chemotherapy with cyclophosphamide (C), epirubicin (E), and 5-fluorouracil (F) were assessed in 10 patients with Stage 2 (node positive) breast cancer. Doses of C and F were 600 mg/m2 and E was 75 mg/m2. Moderate granulocytopenia (median count = 610/mm3) occurred on day 14 of the first 21 day treatment course and was the main toxicity encountered with treatment, although there were no episodes of granulocytopenic fever. Grade 3 or 4 vomiting occurred in 40% and significant alopecia in 30% of patients. Four patients experienced transient asymptomatic decreases in calculated radionuclide cardiac ejection fraction of ≥ 10% but no signs or symptoms of cardiac failure were observed. If epirubicin proves to be less cardiotoxic than doxorubicin, this combination would merit further evaluation as potential adjuvant therapy for early breast cancer.

Original languageEnglish (US)
Pages (from-to)195-198
Number of pages4
JournalInvestigational New Drugs
Volume6
Issue number3
DOIs
StatePublished - Sep 1 1988

Fingerprint

Epirubicin
Adjuvant Chemotherapy
Fluorouracil
Cyclophosphamide
Breast Neoplasms
Doxorubicin
Agranulocytosis
Anthracyclines
Alopecia
Radioisotopes
Signs and Symptoms
Vomiting
Fever
Therapeutics
Heart Failure

Keywords

  • 5-fluorouracil
  • adjuvant chemotherapy
  • cyclophosphamide
  • epirubicin

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Phase I trial of adjuvant chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil (CEF) for stage II breast cancer. / Jones, Stephen E.; Mennel, Robert G.; Peters, George N.; Westrick, Mary Alice; Brooks, Barry D.; Knox, Sally Moot; McGuffey, Patty.

In: Investigational New Drugs, Vol. 6, No. 3, 01.09.1988, p. 195-198.

Research output: Contribution to journalArticle

Jones, Stephen E. ; Mennel, Robert G. ; Peters, George N. ; Westrick, Mary Alice ; Brooks, Barry D. ; Knox, Sally Moot ; McGuffey, Patty. / Phase I trial of adjuvant chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil (CEF) for stage II breast cancer. In: Investigational New Drugs. 1988 ; Vol. 6, No. 3. pp. 195-198.
@article{e7a17737d46047de86e59a88449a268b,
title = "Phase I trial of adjuvant chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil (CEF) for stage II breast cancer",
abstract = "Epirubicin is a new anthracycline with a potentially more favorable toxicity profile than the parent compound, doxorubicin. Accordingly, the feasibility and toxicity of 6 courses of adjuvant chemotherapy with cyclophosphamide (C), epirubicin (E), and 5-fluorouracil (F) were assessed in 10 patients with Stage 2 (node positive) breast cancer. Doses of C and F were 600 mg/m2 and E was 75 mg/m2. Moderate granulocytopenia (median count = 610/mm3) occurred on day 14 of the first 21 day treatment course and was the main toxicity encountered with treatment, although there were no episodes of granulocytopenic fever. Grade 3 or 4 vomiting occurred in 40{\%} and significant alopecia in 30{\%} of patients. Four patients experienced transient asymptomatic decreases in calculated radionuclide cardiac ejection fraction of ≥ 10{\%} but no signs or symptoms of cardiac failure were observed. If epirubicin proves to be less cardiotoxic than doxorubicin, this combination would merit further evaluation as potential adjuvant therapy for early breast cancer.",
keywords = "5-fluorouracil, adjuvant chemotherapy, cyclophosphamide, epirubicin",
author = "Jones, {Stephen E.} and Mennel, {Robert G.} and Peters, {George N.} and Westrick, {Mary Alice} and Brooks, {Barry D.} and Knox, {Sally Moot} and Patty McGuffey",
year = "1988",
month = "9",
day = "1",
doi = "10.1007/BF00175397",
language = "English (US)",
volume = "6",
pages = "195--198",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - Phase I trial of adjuvant chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil (CEF) for stage II breast cancer

AU - Jones, Stephen E.

AU - Mennel, Robert G.

AU - Peters, George N.

AU - Westrick, Mary Alice

AU - Brooks, Barry D.

AU - Knox, Sally Moot

AU - McGuffey, Patty

PY - 1988/9/1

Y1 - 1988/9/1

N2 - Epirubicin is a new anthracycline with a potentially more favorable toxicity profile than the parent compound, doxorubicin. Accordingly, the feasibility and toxicity of 6 courses of adjuvant chemotherapy with cyclophosphamide (C), epirubicin (E), and 5-fluorouracil (F) were assessed in 10 patients with Stage 2 (node positive) breast cancer. Doses of C and F were 600 mg/m2 and E was 75 mg/m2. Moderate granulocytopenia (median count = 610/mm3) occurred on day 14 of the first 21 day treatment course and was the main toxicity encountered with treatment, although there were no episodes of granulocytopenic fever. Grade 3 or 4 vomiting occurred in 40% and significant alopecia in 30% of patients. Four patients experienced transient asymptomatic decreases in calculated radionuclide cardiac ejection fraction of ≥ 10% but no signs or symptoms of cardiac failure were observed. If epirubicin proves to be less cardiotoxic than doxorubicin, this combination would merit further evaluation as potential adjuvant therapy for early breast cancer.

AB - Epirubicin is a new anthracycline with a potentially more favorable toxicity profile than the parent compound, doxorubicin. Accordingly, the feasibility and toxicity of 6 courses of adjuvant chemotherapy with cyclophosphamide (C), epirubicin (E), and 5-fluorouracil (F) were assessed in 10 patients with Stage 2 (node positive) breast cancer. Doses of C and F were 600 mg/m2 and E was 75 mg/m2. Moderate granulocytopenia (median count = 610/mm3) occurred on day 14 of the first 21 day treatment course and was the main toxicity encountered with treatment, although there were no episodes of granulocytopenic fever. Grade 3 or 4 vomiting occurred in 40% and significant alopecia in 30% of patients. Four patients experienced transient asymptomatic decreases in calculated radionuclide cardiac ejection fraction of ≥ 10% but no signs or symptoms of cardiac failure were observed. If epirubicin proves to be less cardiotoxic than doxorubicin, this combination would merit further evaluation as potential adjuvant therapy for early breast cancer.

KW - 5-fluorouracil

KW - adjuvant chemotherapy

KW - cyclophosphamide

KW - epirubicin

UR - http://www.scopus.com/inward/record.url?scp=0023710387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023710387&partnerID=8YFLogxK

U2 - 10.1007/BF00175397

DO - 10.1007/BF00175397

M3 - Article

C2 - 2847991

AN - SCOPUS:0023710387

VL - 6

SP - 195

EP - 198

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 3

ER -